Northern Ireland
Almac has secured planning permission for major expansion plans that could potentially see the company create over 500 jobs during the next five years. The global company which provides integrated research, development and manufacturing services to pharmaceutical and biotech companies internationally, has experienced a substantial rate of growth at its Craigavon headquarters. Anticipating future growth requirements, Almac has acquired an adjacent 5.4 acre site and will shortly embark on the first phase of development there.
In 2008 staff numbers in the UK rose by 15% to 1,426 and in the US by 10% to 762. The company also announced the creation of 128 new graduate and research positions in the first two months of 2009.
The initial phase of the planned further development will see Almac construct a large three-story office unit to accommodate over 220 existing staff and expected recruits. For the second phase of expansion the company obtained outline planning permission for a new research facility as well as a new distribution unit to expand existing capacity.
The plans are expected to lead to additional posts across the Group comprising a mix of administrative and support staff as well as a significant proportion of graduate positions.
As well as the continued construction of their new $112 million North American Headquarters, over the past eighteen months Almac have invested around £10m at the Craigavon site in a new laboratory block and a specialist cold storage facility for clinical trial materials. When completed the new facilities are expected to represent another capital investment on a similar scale.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.